Showing results (471-480 of 528) with videos related to

Sort By:
Pageof 53
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trialEnrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, et al.
Frontiers in Oncology|July 24, 2024
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT studyMarco Sposito, Lorenzo Belluomini, Riccardo Nocini, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2022
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequencesFabrizio Tabbò, Lucia Anna Muscarella, Elisa Gobbini, et al.
Cancer Discovery|July 12, 2020
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated MacrophagesIlaria Marigo, Rosalinda Trovato, Francesca Hofer, et al.
Scientific Reports|October 6, 2025
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancerMarco Sposito, Lorenzo Belluomini, Riccardo Nocini, et al.
Virchows Archiv : an International Journal of Pathology|January 3, 2024
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectivesMichele Simbolo, Giovanni Centonze, Anastasios Gkountakos, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Oncoimmunology|September 18, 2023
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patientsAnnalisa Adamo, Cristina Frusteri, Sara Pilotto, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort studyIgor Gomez-Randulfe, Federico Monaca, Ornella Cantale, et al.
Ebiomedicine|February 10, 2024
Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancerFrancesca Di Modugno, Anna Di Carlo, Sheila Spada, et al.
Pageof 53